Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer.

Autor: Karacin C; Department of Medical Oncology, University of Health Sciences, Dr Abdurrahman Yurtaslan Ankara Oncology Training & Research Hospital, Ankara, Turkey., Sunar V; Depatment of Medical Oncology, Losante Children & Adult Hospital, Ankara, Turkey., Urakci Z; Departmen of Medical Oncology, Dicle University, Diyarbakir, Turkey., Yilmaz A; Department of Medical Oncology, Atatürk University Training Hospital, Erzurum, Turkey., Ayhan M; Department of Medical Oncology, Kartal Training & Research Hospital, Istanbul, Turkey., Ersoy M; Department of Medical Oncology, Osmangazi University, Eskisehir, Turkey., Guven DC; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey., Erturk I; Department of Medical Oncology, University of Health Sciences, Gulhane Training & Research Hospital, Ankara, Turkey., Durmus Y; Department of Gynecology, Etlik Zubeyde Hanim Training & Research Hospital, Ankara, Turkey., Karacin P; Department of Gynecology, Etlik Zubeyde Hanim Training & Research Hospital, Ankara, Turkey., Boran N; Department of Gynecology, Etlik Zubeyde Hanim Training & Research Hospital, Ankara, Turkey., Ustun YE; Department of Gynecology, Etlik Zubeyde Hanim Training & Research Hospital, Ankara, Turkey., Meydan M; Department of Gynecology, Zekai Tahir Burak Training & Research Hospital, Ankara, Turkey., Dogan M; Department of Medical Oncology, University of Health Sciences, Dr Abdurrahman Yurtaslan Ankara Oncology Training & Research Hospital, Ankara, Turkey., Oksuzoğlu B; Department of Medical Oncology, University of Health Sciences, Dr Abdurrahman Yurtaslan Ankara Oncology Training & Research Hospital, Ankara, Turkey., Ates O; Department of Medical Oncology, University of Health Sciences, Dr Abdurrahman Yurtaslan Ankara Oncology Training & Research Hospital, Ankara, Turkey., Karaca M; Department of Medical Oncology, Antalya Training & Research Hospital, Antalya, Turkey., Uncu D; Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara, Turkey., Ergun Y; Department of Medical Oncology, Antalya City Hospital, Antalya, Turkey., Arik Z; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Jazyk: angličtina
Zdroj: Future oncology (London, England) [Future Oncol] 2024 Feb; Vol. 20 (4), pp. 207-214. Date of Electronic Publication: 2024 Feb 08.
DOI: 10.2217/fon-2023-0763
Abstrakt: Aim: To investigate the efficacy and safety of bevacizumab in patients with recurrent low-grade serous ovarian carcinoma. Materials & methods: The data of patients who received at least two cycles of bevacizumab in combination with chemotherapy were retrospectively recorded. Results: The median age of 51 patients was 56 (range: 33-75) years. The complete response rate was 10.4% and the partial response rate was 43.7%. The objective response rate was 54.1%. Median progression-free survival was 15.9 months (95% CI: 9.1-22.6) and median overall survival was 42.5 months (95% CI: 37.2-47.8). Conclusion: Bevacizumab with chemotherapy is an effective option for treating recurrent ovarian low-grade serous carcinoma.
Databáze: MEDLINE